This study investigated the effect of CD20-positive B-cell depletion on central nervous system (CNS) white and gray matter pathology in experimental autoimmune encephalomyelitis in common marmosets, a relevant preclinical model of multiple sclerosis. Experimental autoimmune encephalomyelitis was induced in 14 marmosets by immunization with recombinant human myelin oligodendrocyte glycoprotein in complete Freund adjuvant. At 21 days after immunization, B-cell depletion was achieved by weekly intravenous injections of HuMab 7D8, a humanYanti-human CD20 antibody that cross-reacts with marmoset CD20. In vivo magnetic resonance imaging showed widespread brain white matter demyelination in control marmosets that was absent in CD20 antibodyYtreated marmosets. High-contrast postmortem magnetic resonance imaging showed white matter lesions in 4 of the 7 antibody-treated marmosets, but these were significantly smaller than those in controls. The same technique revealed gray matter lesions in 5 control marmosets, but none in antibody-treated marmosets. Histologic analysis confirmed that inflammation, demyelination, and axonal damage were substantially reduced in brain, spinal cord, and optic nerves of CD20 antibodyYtreated marmosets. In conclusion, CD20-postive B-cell depletion by HuMab 7D8 profoundly reduced the development of both white and gray matter lesions in the marmoset CNS. These data underline the central role of B cells in CNS inflammatory-demyelinating disease.
INTRODUCTION
Multiple sclerosis (MS) is a long-term neurologic disease characterized by inflammation and demyelination in central nervous system (CNS) white matter (WM) and gray matter (GM) (1, 2) . It is generally believed that CNS pathology involves an (auto)immune attack mediated by CD4-positive and CD8-positive T cells, macrophages, and autoantibodies (3) . Recent studies have highlighted a prominent pathogenic role for B cells in MS that could not be explained by removal of the source of autoantibody production, suggesting other pathogenic mechanisms mediated by B cells (4Y6). Depletion of B cells with the chimeric antiYCD20 antibody rituximab has reduced the relapse rate in patients with relapsing-remitting MS (RRMS) (4, 5, 7) . The remarkable clinical effect of B-cell depletion in RRMS was supported by the demonstration using magnetic resonance imaging (MRI) that the total number and volume of T2 lesions and the number of new gadoliniumenhancing brain WM lesions were significantly reduced (4, 5) .
This study was undertaken to obtain proof-of-principle that B cells are a valid target for antibody-mediated therapy, aiming at the prevention of injury to CNS WM and GM. We investigated this in a valid preclinical MS model, experimental autoimmune encephalomyelitis (EAE) in common marmosets (8, 9) . This model is characterized by widespread demyelination of both WM and GM that mimics the pathologic findings in MS patients (10, 11) . The experiment was performed with 2 groups of marmosets in which EAE was induced by a single immunization with recombinant human myelin oligodendrocyte glycoprotein (rhMOG) in complete Freund adjuvant. In 1 group, depletion of CD20-positive B cells was induced at 21 days after immunization using a humanYanti-human CD20 antibody (HuMab 7D8) (12, 13) . This antibody induces profound and long-lasting depletion of CD20-positive B cells from the circulation and lymphoid organs of marmosets (14) . The second group received placebo treatment with an equivalent volume of phosphate-buffered saline (PBS). Treatment was started late after priming to model intervention in an ongoing immunopathogenic process, while achieving complete B-cell depletion before disease onset in early EAE responders (15) .
The immunologic changes caused by CD20-positive Bcell depletion in marmoset EAE, that is, marked changes in autoantibody levels as well as T-cell activation and cytokine profiles, have been reported (14) . Here, we report the dramatic effects on the CNS pathology.
MATERIALS AND METHODS

Animals
Healthy adult common marmoset monkeys used in this study (n = 14) were randomly selected from the outbred colony at the Biomedical Primate Research Centre (Rijswijk, the Netherlands) ( Table 1) . Included animals had been determined to be healthy by routine physical, hematologic, and biochemical examinations by a veterinarian. The mean body weights of the marmosets in the control and treatment groups were 321 T 30 and 342 T 49 g, respectively. The marmosets were pairhoused under conventional conditions in spacious cages and were under intensive veterinary observation throughout the study. The daily diet consisted of commercial food pellets for New World monkeys (Special Diet Services, Witham, Essex, UK), supplemented with raisins, marshmallows, biscuits, and fresh fruit. Drinking water was provided ad libitum. All study protocols and experimental procedures were reviewed and approved by the institute's ethics committee before the start of the study according to the Dutch law on animal experimentation. All animal studies were carried out in accordance with EU directive 86/609/EEC and GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals.
Experimental Autoimmune Encephalomyelitis Induction
Experimental autoimmune encephalomyelitis was induced with a recombinant protein encompassing the extracellular domain of human MOG produced in Escherichia coli (residues 1Y125; rhMOG) and purified as previously described (16) . The inoculum contained 100 Kg of rhMOG in 300 Kl of PBS emulsified with 300 Kl of complete Freund adjuvant (containing Mycobacterium butyricum; Difco Laboratories, Detroit, MI). The 600-Kl emulsion was injected at 4 locations into the dorsal skin under alfaxalone anesthesia (10 mg/kg; alfaxan; Vetoquinol, Den Bosch, the Netherlands).
Clinical signs were scored daily by 2 independent observers using a previously described semiquantitative scale (17). Briefly, 0 = no clinical signs; 0.5 = apathy, altered walking pattern without ataxia; 1 = lethargy, tail paralysis, tremor; 2 = ataxia, optic disease; 2.25 = monoparesis; 2.5 = paraparesis, sensory loss; 3 = paraplegia or hemiplegia; 4 = quadriplegia; and 5 = death due to EAE. For ethical reasons, marmosets were killed once complete paralysis of hind limbs (EAE score 3.0) was observed, or at the predetermined end point of the study, which was arbitrarily set at 15 weeks.
Marmosets selected for necropsy were first deeply sedated by intramuscular injection of alfaxalone (10 mg/kg) followed by infusion of pentobarbital sodium (Euthesate; Apharmo, Duiven, the Netherlands). Control  M02052  1  M  84  307  46  V  59  M06061  2  M  31  306  41  54  55  M06081 §  M  28  283  V  V  33  M07021  3  M  24  339  66  83  83  M07029  4  M  24  377  78  91  91  M07048  5  M  21 
CD20 Antibody Treatment
HuMab 7D8 is a human IgG1J monoclonal antibody directed against human CD20 (12, 13) that cross-reacts with marmoset CD20 (data not shown). Seven marmosets received a single intravenous dose of 20 mg/kg HuMab 7D8 at postsensitization day (PSD) 21 to induce robust B-cell depletion from blood and lymph nodes. To maintain plasma trough levels of HuMab 7D8 greater than 5 to 10 Kg/ml (18), 5 mg/kg was administered intravenous every week. The 7 control animals received a weekly intravenous injection with 1 mL/kg sterile PBS (Table 1) .
Magnetic Resonance Imaging
In vivo experiments were performed using a 4.7-T horizontal bore nuclear magnetic resonance spectrometer (Varian, Palo Alto, CA) after sedation of the animal with alfaxalone (10 mg/kg). Imaging sequences included quantitative T 2 relaxation time (T 2 ), magnetization transfer ratio (MTR), and Gadovist leakage imaging. White matter lesions, WM, normalappearing WM (NAWM), and GM areas were defined for calculation of MR characteristics. White matter was measured as total WM in the first caudal to rostral slice that showed the complete corpus callosum. Normal-appearing WM was defined in this slice as the WM minus the WM lesions present in this slice. The WM parameter represents total WM and, therefore, includes NAWM as well as WM lesions. In animals in which WM lesions were absent, no NAWM was calculated because this is the same as WM. See also supplemental methods for a detailed description (Appendix, Supplemental Digital Content 1, http://links.lww.com/NEN/A275).
For postmortem imaging, 1 cerebral hemisphere collected at necropsy was fixed in 4% buffered formalin and transferred after 14-day fixation into buffered saline containing sodium azide to stabilize MR relaxation time characteristics (19) . Brains were submerged in nonmagnetic oil (Fomblin; perfluorinated polyether; Solvay Solexis, Weesp, the Netherlands) to prevent unwanted susceptibility artifacts. Highcontrast postmortem MR images were recorded on a 9.4-T horizontal bore nuclear magnetic resonance spectrometer (Varian) equipped with a quadrature coil (RAPID; Biomedical, Rimpar, Germany). T 2 and MTR images were collected as described in supplemental methods (Appendix, Supplemental Digital Content 1, http://links.lww.com/NEN/A275). Inversion recovery, in which the signal from the GM was suppressed, was performed to facilitate the detection of GM lesions. Image resolution was more than 10 times higher than the resolution obtained with in vivo MRI. Next to the areas described previously, GM lesions and normal-appearing GM areas were also outlined (Appendix, Supplemental Digital Content 1, http://links.lww.com/NEN/A275).
Histology and Immunohistochemistry
Frozen and fixed tissues were processed for examination with histologic and immunohistochemical techniques as previously described (20Y22). Sections were stained with Luxol fast blueYperiodic acidYSchiff stain and by immunohistochemistry for myelin proteolipid protein (PLP), MRP14, MHC class II, CD3, CD20, complement C9neo, IgG, and SMI-32. The CD20 antibody used to stain B cells reacts with another epitope than HuMab 7D8.
Analysis of Demyelination
Demyelination was assessed as follows: brain sections stained for PLP were photographed at 2.5Â magnification; images were then imported in the Scion Image program (freeware downloaded from www.scioncorp.com), an image processing and analysis program based on NIH Image developed at the National Institutes of Health, Bethesda, MD. In density slice mode, first the total area of the section was measured. After this, total WM (approximately 40 mm 2 ) was measured and subtracted from the total area, resulting in the GM area (approximately 100 mm 2 ). Lesions in WM and GM were selected by freehand mode, and their sizes were measured. Finally, the demyelination in WM or GM was calculated as percentage of total WM or GM. For the spinal cords, 8 sections from each animal (amounting to approximately 6 cm 2 in total) were analyzed. Demyelination in optic nerve was scored as follows: + = demyelination, T = some demyelination, j = no demyelination.
Statistics
Data are presented as mean T SEM of 6 control and 7 treated marmosets. Statistical analysis was performed using GraphPad Prism 5.0b for Mac OS X. Survival was analyzed using log-rank test. Differences between control and treated marmosets were analyzed using the Mann-Whitney U test. Differences between WM lesions and WM or NAWM within the control group were analyzed by the paired Student t-test. p G 0.05 was considered significant.
RESULTS
Clinical Course and In Vivo Brain MRI Recording
One marmoset (M06081) from the control (PBS-treated) group died unexpectedly at PSD 33 from cardiac failure and was therefore excluded from further analyses. Clinical analysis of EAE development in 6 control and 7 antibody-treated monkeys showed that depletion of CD20-positive B cells significantly prevented the development of clinical signs (14) ( Table 1 , survival time to score 2: p = 0.0291; survival time to death with clinical signs: p = 0.0021).
Before the start of the experiment, the animals were paired based on age and body weight. Of each pair, 1 monkey received control substance and 1 monkey the therapeutic antibody ( Table 1 ). The first MRI was planned before the start of the treatment, at PSD 18. When at least 1 monkey of a pair had experienced evident neurologic signs (clinical score Q2), a second MRI was made of both paired monkeys to assess whether the 2 monkeys had a different brain lesion load.
At PSD 18, none of the animals showed MRI-detectable brain lesions, although the presence of small nonfocal pathologic alterations invisible with the applied MRI techniques could not formally be excluded (Fig. 1A) . In 4 pairs, neurologic signs (score Q2) were first observed in the control monkey, whereas at that time, the 4 paired HuMab 7D8Ytreated monkeys had no neurologic signs (pairs 2, 3, 4, and 5). The MRI of the other 2 pairs was made because the treated animal (pair 6) or both animals (pair 1) displayed clinical score 2. In 4 of the 6 control animals, WM lesions were detected at the second MRI (Table 2 and Fig. 1A ). There were no detectable brain WM lesions in 2 control animals (i.e. M07021 and M07080); the latter was asymptomatic at the day the MRI was made. Brain lesions were detected with in vivo MRI in none of the HuMab 7D8-treated animals, although two animals (M04096 and M07095) had experienced a short episode of clinical score 2 (1 day) only a few days before the MRI was made (Table 2 ).
In Vivo MRI Analysis
Several clinically relevant MRI parameters were quantitated in WM, NAWM, GM, and WM lesion areas (Figure, Supplemental Digital Content 2, http://links.lww.com/NEN/A276). Typical MRI characteristics of WM lesions, namely, increased T 2 , decreased MTR, and increased Gadovist leakage compared with WM or NAWM, were found in control animals (Table 3; Table, Supplemental Digital Content 3, http://links.lww.com/NEN/A277). In controls, the MTR was significantly lower in WM lesions than in NAWM, which is compatible with the presence of inflammation and demyelination. No WM lesions were observed in HuMab 7D8Ytreated animals. We compared WM of treated animals with NAWM of controls because they both reflect WM without WM lesions, but differences between NAWM of control and WM of treated animals were not statistically significant.
The increment of T1 signal intensity by intravenous Gadovist was somewhat lower in the WM of HuMab 7D8Y treated animals than in WM and NAWM of control animals, suggesting that there is a higher overall increase of bloodbrain barrier (BBB) permeability throughout the complete WM in the control animals. The permeability of the BBB, as indicated by albumin deposition, was observed in the brain parenchyma of both control and treated animals (data not shown). No statistically significant differences between the groups were observed for the GM with respect to volume, T 2 , MTR, or Gadovist leakage (Table 3 ; Table, Supplemental Digital Content 3, http://links.lww.com/NEN/A277).
In conclusion, these data demonstrate that depletion of CD20-positive B cells 3 weeks after EAE induction prevented the development of detectable WM lesions in vivo.
Postmortem MRI of the Brain
To maximize the detection of EAE-associated pathology, formalin-fixed brain hemispheres were examined with high-resolution MRI at 9.4-T field strength. The voxel volume of the postmortem images was more than 10-fold higher than for the in vivo images (7.2 vs 97.6 Â 10 j3 mm 3 ), thereby facilitating the detection of small lesions. Gray matter lesions were also detectable in these images, particularly when the MR signal of GM was suppressed ( in contrast to control animals. These data suggest that the lesions of treated animals had less myelin damage. Gray matter lesion formation was detected in 5 of the 6 control animals, but in none of the HuMab 7D8Ytreated animals ( Fig. 1B and Table 4 ; Table, Supplemental Digital Content 4, http://links.lww.com/NEN/A278). Differences in MR characteristics between GM lesions and surrounding unaffected tissue (GM/normal-appearing GM) were much lower than the differences observed for WM lesions versus NAWM (WM/NAWM). Thus, depletion of CD20-positive B cells not only reduced the development of WM lesions but also prevented the development of GM lesions.
CNS WM Pathology
Histologic analysis revealed actively demyelinating brain lesions in all control animals, even in the animals that had only small MRI-detectable lesions on the postmortem images (M07029 and M07080). By contrast, the small WM lesions detected with high-contrast postmortem MRI in 4 HuMab 7D8Ytreated animals showed no histologic signs of active demyelination (Table 5; Table, Supplemental Digital Content 4, http://links.lww.com/NEN/A278). Demyelination in the spinal cord was observed in 5 of the 6 control animals but in only 2 of the 7 treated animals. The percentage demyelination was significantly smaller in treated animals. Demyelination in the optic nerve was observed in 4 of the 6 control but in none of the treated animals (Figs. 2AYF and Table 5 ).
Many inflammatory lesions were observed in the brains of all 6 control animals. Despite the absence of demyelination in the brain, 4 of the 7 HuMab 7D8Ytreated animals had some small inflammatory lesions. This explains the detection of some small lesions by high-contrast postmortem MRI in the absence of demyelination. In the spinal cord, 5 of the 6 control animals had prominent inflammation in the spinal cord. Spinal cord lesions were undetectable in the control animal that was killed without clinical signs at the end of the study (M07048). Spinal cord lesions were also absent in 4 of the 7 antibody-treated animals and were small in the other 3. The number of B and T cells was determined in spinal cord. As expected, no B cells were observed in the spinal cord of HuMab 7D8Ytreated animals. T cells were observed in all control animals and in 6 of the 7 HuMab 7D8Ytreated animals. The number of T cells in these treated animals was, in some cases, higher than in the control animals, for example, in M07085 (43.1 CD3-positive cells/mm 2 ), but the average number of T cells was less in HuMab 7D8Ytreated animals than in control animals ( Table 5 ). Macrophages were profoundly reduced in the spinal cord of HuMab 7D8Y treated animals but were clearly present in control animals (Figs. 2GYL) . Deposition of IgG and C9neo was observed in brain and spinal cord of control animals, but not in HuMab 7D8Ytreated animals (data not shown), suggesting that antibody-mediated immunity is absent in HuMab 7D8Y treated animals. Overall, the severity of inflammation in the spinal cord was significantly higher in control animals than in the HuMab 7D8Ytreated animals. Inflammation in the optic nerve was detected in 3 of the 6 controls but in none of the treated animals (Table 5) .
Although it is uncertain whether axonal damage can occur in the absence of demyelination, we investigated whether axonal damage occurs in control and B-cell depleted animals. Figure 3 shows a representative example of a control and a HuMab 7D8Ytreated marmoset. A demyelinating WM lesion of a control marmoset is shown containing many MHC class IIYpositive cells and T cells. Increased immunopositivity was found for the axonal damage marker SMI-32 (23) in this lesion. Only low SMI-32 immunoreactivity was observed in the treated animals, suggesting that limited axonal damage was present. Overall, these data suggest that B-cell depletion reduces demyelination, inflammation, and axonal damage in the WM.
Gray Matter Pathology
Gray matter demyelination in the marmoset EAE model can be substantially more extensive than the usually focal demyelination in WM (Fig. 4) . Note that lesions in the depicted control animal were not only observed in the cortical GM but also in the hippocampus (Figs. 4A, B) . Gray matter lesions were detected in 5 control animals by MRI and in 3 of these animals, this was confirmed by histology. Histologic analysis confirmed the MRI observation that no GM lesions could be found in the HuMab 7D8Ytreated animals (Fig. 4 and Table 5 ; Table, Supplemental Digital Content 4, http://links.lww.com/NEN/A278). The cortical lesions in the control animals consist of PLP-phagocytosing macrophages/ microglia, T cells, and B cells (Figs. 4CYH) . In contrast, no demyelination or MRP14-positive macrophages/activated microglia were observed in the treated animals (Figs. 4IYL) .
Gray matter lesions in control animals are positive for SMI-32, indicating axonal damage. Less SMI-32 positivity was observed in HuMab 7D8Ytreated animals (Fig. 5) . Thus, depletion of CD20-positive B cells dramatically attenuated the development of MS-like pathology affecting WM and GM in all parts of the marmoset CNS.
DISCUSSION
Clinical trials in RRMS patients have shown marked clinical benefits of CD20-positive B-cell depletion by rituximab, including a reduction of relapse frequency and contrastenhancing lesions in the cerebral WM (4, 5) . As a first step toward understanding the presumed multifaceted pathogenic role of B cells in CNS-demyelinating disease, we investigated the effect of CD20-positive B-cell depletion in the rhMOGinduced EAE model in marmosets. This model is characterized by MS-like lesions developing in CNS WM and GM, which may be induced by the synergistic action of autoreactive T cells and autoantibodies (9, 10, 15, 24) .
We found that the depletion of CD20-positive B cells, which was induced well after EAE induction, led to protection against clinical EAE and reduced the total volume of brain WM lesions. In addition, there was suppression of demyelination in the optic nerve and in spinal cord similar to that shown in a mouse EAE model (25) . B-cell depletion not only reduces lesion volume but also changes the pathologic features of the lesions, that is, macrophages, complement, and antibodies were absent in the lesions.
The most important finding in the current study is the complete absence of demyelination and axonal damage in the GM. To our knowledge, this is the first documented evidence that GM pathology can be prevented with a CD20-positive B-cell depleting antibody. Cortical GM pathology is a relatively recently recognized aspect of the complex MS pathology that may contribute to cognitive impairment (2, 26) . The pathology of GM lesions differs from WM lesions in a low number of lymphocytes, low level of complement deposition, and the absence of BBB disruption (27Y29). However, there is marked activation of microglia at the borders of GM lesions (27, 30) . The pathogenic processes underlying GM lesions are still unknown, but several mechanisms have been proposed (2) . Gray matter lesions may start in the GM via a different pathogenic process than WM lesions or they are a consequence of damage in the WM. Although the role of B cells in GM lesion pathogenesis is unknown and their number is lower in GM lesions than in WM lesions, this study indicates that B cells are intimately engaged in the development of GM lesions. The association of meningeal B-cell follicles with severe cortical pathology in secondary progressive MS might be one explanation as to how B-cell depletion prevents GM pathology, but further research is needed (31) .
The mechanisms via which B cells contribute to MS and which mechanisms are affected by B-cell depletion are not known. The most investigated role of B cells in MS is autoantibody production. According to a widely supported concept, autoimmune demyelination in MS can take place in the absence (pattern 1 lesion) or presence (pattern 2 lesion) of IgG antibody binding to myelin (32) . This view is strongly supported by findings in the marmoset EAE model (15, 33Y35). Although anti-CD20 treatment does not target plasma cells, anti-MOG IgG is reduced in the circulation of mice and marmosets in which B cells were depleted (14, 25, 36, 37) . In addition, no IgG or C9neo deposition was observed in the CNS of HuMab 7D8Ytreated marmosets. This may partly explain the reduced demyelination observed, but in the rituximab trials in RRMS, significant reduction of total serum IgG levels was not found; however, the specific effect on antimyelin antibodies has not been determined (4, 5) . The authors of these articles speculate that serum IgG levels were not affected by rituximab because plasma cells do not express CD20 and were therefore not depleted (38) . This raises the question as to whether the clinical effect is mediated by another mechanism via which B cells can induce demyelination.
One mechanism that may be affected by B-cell depletion is the production of B-cell cytokines. It has been demonstrated that B cells in MS patients exhibit increased production of lymphotoxin and tumor necrosis factor (6, 39) . As suggested by Lund and Randall (40) , it may also be that B-cell depletion disrupts the feed-forward loop between B cells and T cells leading to more regulatory T cells. As a consequence repopulated B cells will also be regulatory. Indeed, several studies show that regulatory B cells can protect against EAE (25, 41) .
B cells may also function as antigen presenting cells leading to T-cell activation. Reduced T-cell activity after CD20-positive B-cell depletion has been observed in various experimental systems, including naive mice, NOD mice, 2 mouse models for arthritis, and mice infected with Listeria monocytogenes (42, 43) . We have previously reported that the expression of clinical signs of EAE is associated with the activation of a unique subset of cytotoxic IL-17A producing T cells, which mediate widespread CNS demyelination in the absence of anti-MOG antibodies (15, 35) . Separately, we have reported the observation that B-cell depletion by HuMab 7D8 significantly reduced T-cell proliferation and cytokine production in spleen and lymph nodes of rhMOGimmunized marmosets (the same animals as used in the present study) (14) . Importantly, the number of T cells that could be observed in the CNS of HuMab 7D8Ytreated animals was reduced. Similar results have been observed in mouse EAE models, namely, both T H 1 and T H 17 cell numbers were reduced in spleen and CNS (36, 37) . Because demyelination in EAE-affected marmosets can occur in the absence of autoantibodies directed against rhMOG and MOG peptides, we hypothesize that the abrogation of CNS injury after B-cell depletion might be caused by the prevention of the activation of autoreactive T cells. This hypothesis is supported by our recent observation that similar results were obtained after B-cell depletion in an antibody-independent EAE model, that is, EAE in marmosets induced by MOG34-56 in IFA (15) .
In conclusion, B-cell depletion effectively prevents the development of inflammation, demyelination, and axonal damage in the brain WM and GM as well as in spinal cord and optic nerve. This emphasizes that CD20-positive B cells have a central pathophysiologic role in inflammation, demyelination, and axonal damage and are an important target of therapies aiming at abrogation of lesion development in all areas of the CNS.
